Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 5/20 | 0.32 |
| ▸ | CA1 | P00915 | 3/20 | 0.31 |
| ▸ | CA9 | Q16790 | 3/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29331693 | 0.95 | ALDH1A1 (0.39) | ALDH1A1KMT2AKDM4ESMN1; SMN2ALOX15 | |
| SCHEMBL26370525 | 0.94 | ALDH1A1 (0.39) | ALDH1A1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL1996638 | 0.90 | ALDH1A1 (0.41) | ALDH1A1KMT2AKDM4ESMN1; SMN2ALOX15 | |
| Dimethylamine SCHEMBL1996640 | 0.88 | CA2 (0.37) | ALDH1A1KMT2AKDM4ESMN1; SMN2TAAR1 | |
| SCHEMBL21117418 | 0.88 | CA1 (0.36) | ALDH1A1KMT2AKDM4ESMN1; SMN2ALOX15 | |
| SCHEMBL20960341 | 0.87 | ALDH1A1 (0.34) | ALDH1A1KMT2AKDM4E | |
| SCHEMBL21117164 | 0.87 | ALDH1A1 (0.36) | ALDH1A1KMT2AKDM4E | |
| SCHEMBL22317361 | 0.86 | ALDH1A1 (0.44) | ALDH1A1KMT2AKDM4ESMN1; SMN2TAAR1 | |
| SCHEMBL5682361 | 0.86 | ALDH1A1 (0.44) | ALDH1A1KMT2AKDM4ESMN1; SMN2TAAR1 | |
| SCHEMBL21117421 | 0.84 | CA12 (0.44) | KDM4ECA2CA1CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043741-B2 | Conjugated diene-based polymer composition and tire | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2024-07-23 | — | — | US | disclosed |
| US-20230312889-A1 | POLYMER COMPOSITION, METHOD FOR PRODUCING SAME, FORMULATION, CROSSLINKED PRODUCT, AND TIRE | ENEOS MATERIALS CORPORATION (JP) | 2023-10-05 | — | — | US | disclosed |
| US-10894876-B2 | Method for producing modified conjugated diene-based polymer, modified conjugated diene-based polymer, polymer composition, crosslinked body, tire and compound | JSR CORPORATION (JP) | 2021-01-19 | — | — | US | disclosed |
| US-20190194430-A1 | METHOD FOR PRODUCING MODIFIED CONJUGATED DIENE-BASED POLYMER, MODIFIED CONJUGATED DIENE-BASED POLYMER, POLYMER COMPOSITION, CROSSLINKED BODY, TIRE AND COMPOUND | JSR CORPORATION (JP) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894876-B2 | Method for producing modified conjugated diene-based polymer, modified conjugated diene-based polymer, polymer composition, crosslinked body, tire and compound | IGF1R, PHOSPHO1, GAR1 | ALDH1A1 260/4885KMT2A 1043/4885KDM4E 2762/4885 |
| US-20190194430-A1 | METHOD FOR PRODUCING MODIFIED CONJUGATED DIENE-BASED POLYMER, MODIFIED CONJUGATED DIENE-BASED POLYMER, POLYMER COMPOSITION, CROSSLINKED BODY, TIRE AND COMPOUND | IGF1R, PHOSPHO1, GAR1 | ALDH1A1 263/4885KMT2A 1250/4885KDM4E 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.